Quick Answer
ACRO BIOMEDICAL CO., LTD. reported Cash and Equivalents of $18.1 thousand for fiscal year 2020.
ACRO BIOMEDICAL CO., LTD. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2020 | $18.1K | +1889.4% |
| 2019 | $911.00 | -38.1% |
| 2019 | $1.5K | -96.1% |
| 2018 | $37.6K | +3175.9% |
| 2018 | $1.1K | -96.9% |
| 2017 | $36.8K | +1353.2% |
| 2016 | $2.5K | -90.7% |
| 2015 | $27.3K | +594.9% |
| 2014 | $3.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2021 | $215.5K | +56460.1% | +784.7% |
| March 31, 2021 | $24.4K | +129.0% | +34.4% |
| December 31, 2020 | $18.1K | +1889.4% | +11517.3% |
| September 30, 2020 | $156.00 | -89.4% | -59.1% |
| June 30, 2020 | $381.00 | +64.9% | -96.4% |
| March 31, 2020 | $10.6K | +2481.6% | +1067.5% |
| December 31, 2019 | $911.00 | -97.6% | -38.1% |
| September 30, 2019 | $1.5K | +28.2% | +537.2% |
- ACRO BIOMEDICAL CO., LTD. showed an increase of +1889.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2020 period, ACRO BIOMEDICAL CO., LTD.’s cash and equivalents has grown by 361.7% (from $3.9 thousand to $18.1 thousand).
- The most recent figure is from ACRO BIOMEDICAL CO., LTD.’s fiscal year 2020 report (Form 10-K), filed with the SEC on April 2, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: